SARS-CoV-2 pathogenesis

Nature Reviews Microbiology, Journal Year: 2022, Volume and Issue: 20(5), P. 270 - 284

Published: March 30, 2022

Language: Английский

---

ISTH guidelines for antithrombotic treatment in COVID‐19

Journal of Thrombosis and Haemostasis, Journal Year: 2022, Volume and Issue: 20(10), P. 2214 - 2225

Published: July 8, 2022

Language: Английский

---

Pulmonary Thrombosis and Thromboembolism in COVID-19

CHEST Journal, Journal Year: 2021, Volume and Issue: 160(4), P. 1471 - 1480

Published: June 19, 2021

COVID-19, the disease responsible for devastating pandemic that began at end of 2019, has been associated with a significantly increased risk pulmonary thrombosis, even in patients receiving prophylactic anticoagulation. The predilection thrombosis COVID-19 may be driven by least two distinct, but interrelated, processes: hypercoagulable state large-vessel and thromboembolism direct vascular endothelial injury situ microvascular thrombosis. presence explain why hypoxemia is out proportion to impairment lung compliance some pneumonia. Because embolism (PE) pneumonia share many signs symptoms, diagnosing PE can challenging. Given high mortality morbidity severe concern aspects hospital systems have instituted aggressive anticoagulation protocols above standard VTE prophylaxis. In this review, epidemiologic pathophysiologic features, diagnosis, treatment are discussed.

Language: Английский

---

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial

Journal of Thrombosis and Haemostasis, Journal Year: 2021, Volume and Issue: 19(9), P. 2225 - 2234

Published: July 8, 2021

Language: Английский

---

Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation

Frontiers in Cellular and Infection Microbiology, Journal Year: 2022, Volume and Issue: 12

Published: April 5, 2022

Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms long COVID include: persistent viral replication, chronic hypoxia inflammation. Ongoing vascular endothelial damage promotes platelet adhesion coagulation, resulting in impairment various organ functions. Meanwhile, thrombosis will further aggravate vasculitis contributing deterioration. Thus, is essentially a thrombotic sequela. Unfortunately, there currently no effective treatment for COVID. This article summarizes evidence coagulation abnormalities COVID, with focus thrombosis. Extracellular vesicles (EVs) released types cells can carry SARS-CoV-2 through circulation attack distant tissues organs. Furthermore, EVs express tissue factor phosphatidylserine (PS) which Given persistence virus, inflammation are inevitable. Pulmonary structural changes such as hypertension, embolism fibrosis common The impaired lung function again aggravates abnormalities. In this article, we also summarize recent research antithrombotic therapy COVID-19. There increasing that early anticoagulation be improving outcomes. fact, systemic dysfunction caused key factors driving complications Early prophylactic prevent release or remove procoagulant substances, thereby protecting endothelium from damage, reducing sequelae, long-COVID patients.

Language: Английский

---

Heparin: An old drug for new clinical applications

Carbohydrate Polymers, Journal Year: 2022, Volume and Issue: 295, P. 119818 - 119818

Published: July 3, 2022

Language: Английский

---

Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19

Journal of the American College of Cardiology, Journal Year: 2023, Volume and Issue: 81(18), P. 1747 - 1762

Published: March 6, 2023

Language: Английский

---

2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19

Journal of Thrombosis and Haemostasis, Journal Year: 2024, Volume and Issue: 22(6), P. 1779 - 1797

Published: March 18, 2024

Based on emerging evidence from the COVID-19 pandemic, International Society Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in were published 2022. Since then, at least 16 new randomized controlled trials have contributed additional evidence, which necessitated a modification of most previous recommendations. We used again American College Cardiology Foundation/American Heart Association methodology assessment level (LOE) class recommendation (COR). Five recommendations had LOE upgraded to A 2 patients with added. Furthermore, section was added answer questions about vaccination vaccine-induced immune thrombotic thrombocytopenia (VITT), studies provided some evidence. only included or B. Panelists agreed 19 recommendations, 4 nonhospitalized, 5 noncritically ill hospitalized, 3 critically postdischarge patients, as well VITT. strong (COR 1) given (a) use prophylactic dose low-molecular-weight heparin unfractionated hospitalized COVID-19, (b) select this group, therapeutic-dose heparin/unfractionated preference dose, (c) antiplatelet factor enzyme immunoassays diagnosing against 3) addition an agent patients. These international provide countries diverse healthcare resources vaccine availability.

Language: Английский

---

The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?

Cytokine, Journal Year: 2021, Volume and Issue: 144, P. 155593 - 155593

Published: May 25, 2021

Language: Английский

---

Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support

European Respiratory Journal, Journal Year: 2021, Volume and Issue: 60(1), P. 2102532 - 2102532

Published: Nov. 25, 2021

Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19) patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill. We determined whether early (within 48 h) dexamethasone was associated with hospitalised COVID-19 not IRS.We included admitted to US Veterans Affairs hospitals between 7 June 2020 and 31 May 2021 within 14 days after a positive test for severe acute syndrome 2. Exclusions recent prior corticosteroids IRS h. used inverse probability treatment weighting (IPTW) balance exposed unexposed groups, Cox proportional hazards models determine 90-day all-cause mortality.Of 19 973 total (95% men, median age 71 years, 27% black), 15 404 (77%) were without Of these, 3514 out 9450 (34%) no oxygen received 1042 (11%) died; 4472 5954 (75%) low-flow nasal cannula (NC) only 857 (14%) died. In IPTW stratified models, who experienced 76% increased risk (hazard ratio (HR) 1.76, 95% CI 1.47-2.12); there association among NC (HR 1.08, 0.86-1.36).In COVID-19, initiation common those or the first h; instead, we found evidence potential harm. These real-world findings do use IRS.

Language: Английский

---